NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

纖維肌痛症治療藥的全球市場

Fibromyalgia Therapeutics

出版商 Global Industry Analysts, Inc. 商品編碼 997879
出版日期 內容資訊 英文 163 Pages
商品交期: 最快1-2個工作天內
價格
纖維肌痛症治療藥的全球市場 Fibromyalgia Therapeutics
出版日期: 2021年04月01日內容資訊: 英文 163 Pages
簡介

全球纖維肌痛症治療藥的市場規模,預計在分析期間(2020年∼2027年)將以2%的年複合成長率增長,從2020年的28億美元,到2027年達到32億美元。

本報告所分析的市場區隔之一的抗癲癇藥部門,分析期間中預計將以1.8%的年複合成長率增長,達到18億美元。

本報告提供全球纖維肌痛症治療藥市場的相關調查,提供市場佔有率,Covid-19的影響,趨勢和成長要素,各地區的市場分析,競爭情形,主要企業的簡介等資訊。

調查對象企業範例

  • Allergan plc
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo Company Limited
  • Eli Lilly and Company
  • Innovative Med Concepts Inc.
  • Pfizer Inc.
  • SWITCHBIOTECH LLC
  • Zynerba Pharmaceuticals Inc.

目錄

I. 調查手法

II. 摘要整理

  • 市場概要
    • 影響者市場洞察
    • 全球市場的軌跡
    • Covid-19的影響與即將到來的全球景氣衰退
  • 主要企業
  • 趨勢與推動要素
  • 全球市場預測

III. 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 南美
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他南美國家
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東
  • 非洲

IV. 競爭

  • 企業簡介:22公司

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP-6917

Abstract:

Global Fibromyalgia Therapeutics Market to Reach $3.2 Billion by 2027

Amid the COVID-19 crisis, the global market for Fibromyalgia Therapeutics estimated at US$2.8 Billion in the year 2020, is projected to reach a revised size of US$3.2 Billion by 2027, growing at a CAGR of 2% over the analysis period 2020-2027. Antiepileptics, one of the segments analyzed in the report, is projected to record a 1.8% CAGR and reach US$1.8 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Antidepressants segment is readjusted to a revised 2.4% CAGR for the next 7-year period.

The U.S. Market is Estimated at $749.7 Million, While China is Forecast to Grow at 3.7% CAGR

The Fibromyalgia Therapeutics market in the U.S. is estimated at US$749.7 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$613.1 Million by the year 2027 trailing a CAGR of 3.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 0.4% and 1.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 0.7% CAGR.

Other Drug Classes Segment to Record 1.8% CAGR

In the global Other Drug Classes segment, USA, Canada, Japan, China and Europe will drive the 1.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$311.3 Million in the year 2020 will reach a projected size of US$344.6 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$426.7 Million by the year 2027, while Latin America will expand at a 2.6% CAGR through the analysis period.

Select Competitors (Total 22 Featured) -

  • Allergan plc
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo Company Limited
  • Eli Lilly and Company
  • Innovative Med Concepts Inc.
  • Pfizer Inc.
  • SWITCHBIOTECH LLC
  • Zynerba Pharmaceuticals Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Fibromyalgia Syndrome: A Prelude
    • Recent Market Activity
    • Fibromyalgia Therapeutics Market: A Nascent Sector
    • A Glance at the Current & Future Fibromyalgia Therapeutics Portfolio
    • FDA Approved Fibromyalgia Drugs
    • IMC-1: A Revolutionary Combination Therapy
    • Daiichi Sankyo's Mirogabalin Drug Improvises on Lyrica
    • Tonix Pharma Develops Newer Sublingual Formulation of Cyclobenzaprine
    • Understanding Heightened Effect of Pain in Women Due to Fibromyalgia
    • Inconsistencies and Loopholes in Current Fibromyalgia Diagnoses
    • Fibromyalgia Treatment through High-Pressure Oxygen Application
    • EU approves New Device to Treat Fibromyalgia and Migraine
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
    • Allergan plc (Ireland)
    • Boehringer Ingelheim GmbH (Germany)
    • Daiichi Sankyo Company Limited (Japan)
    • Eli Lilly and Company (USA)
    • Innovative Med Concepts, Inc. (USA)
    • Pfizer, Inc. (USA)
    • Pierre Fabre Medicament (France)
    • SWITCHBIOTECH LLC (USA)
    • Zynerba Pharmaceuticals, Inc. (USA)
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Fibromyalgia Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Fibromyalgia Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Fibromyalgia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Antiepileptics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Antiepileptics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Antiepileptics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Antidepressants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Antidepressants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 13: USA Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 14: USA Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 15: USA 15-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 16: Canada Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 17: Canada Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 18: Canada 15-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 19: Japan Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 20: Japan Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 21: Japan 15-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 22: China Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 23: China Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 24: China 15-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 25: Europe Current & Future Analysis for Fibromyalgia Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 26: Europe Historic Review for Fibromyalgia Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 27: Europe 15-Year Perspective for Fibromyalgia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 28: Europe Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 29: Europe Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 30: Europe 15-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 31: France Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 32: France Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 33: France 15-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 34: Germany Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 35: Germany Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 36: Germany 15-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 37: Italy Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 38: Italy Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 39: Italy 15-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 40: UK Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 41: UK Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 42: UK 15-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2020 & 2027
  • SPAIN
    • TABLE 43: Spain Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Spain Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 45: Spain 15-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2020 & 2027
  • RUSSIA
    • TABLE 46: Russia Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 47: Russia Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 48: Russia 15-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 49: Rest of Europe Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Rest of Europe Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 51: Rest of Europe 15-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 52: Asia-Pacific Current & Future Analysis for Fibromyalgia Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 53: Asia-Pacific Historic Review for Fibromyalgia Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 54: Asia-Pacific 15-Year Perspective for Fibromyalgia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
    • TABLE 55: Asia-Pacific Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Asia-Pacific Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 57: Asia-Pacific 15-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2020 & 2027
  • AUSTRALIA
    • TABLE 58: Australia Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 59: Australia Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 60: Australia 15-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2020 & 2027
  • INDIA
    • TABLE 61: India Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 62: India Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 63: India 15-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2020 & 2027
  • SOUTH KOREA
    • TABLE 64: South Korea Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 65: South Korea Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 66: South Korea 15-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2020 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 67: Rest of Asia-Pacific Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Rest of Asia-Pacific Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 69: Rest of Asia-Pacific 15-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2020 & 2027
  • LATIN AMERICA
    • TABLE 70: Latin America Current & Future Analysis for Fibromyalgia Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 71: Latin America Historic Review for Fibromyalgia Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 72: Latin America 15-Year Perspective for Fibromyalgia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
    • TABLE 73: Latin America Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Latin America Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 75: Latin America 15-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2020 & 2027
  • ARGENTINA
    • TABLE 76: Argentina Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 77: Argentina Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 78: Argentina 15-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2020 & 2027
  • BRAZIL
    • TABLE 79: Brazil Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 80: Brazil Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 81: Brazil 15-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2020 & 2027
  • MEXICO
    • TABLE 82: Mexico Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Mexico Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 84: Mexico 15-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2020 & 2027
  • REST OF LATIN AMERICA
    • TABLE 85: Rest of Latin America Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Rest of Latin America Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 87: Rest of Latin America 15-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2020 & 2027
  • MIDDLE EAST
    • TABLE 88: Middle East Current & Future Analysis for Fibromyalgia Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 89: Middle East Historic Review for Fibromyalgia Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 90: Middle East 15-Year Perspective for Fibromyalgia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
    • TABLE 91: Middle East Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Middle East Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 93: Middle East 15-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2020 & 2027
  • IRAN
    • TABLE 94: Iran Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Iran Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 96: Iran 15-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2020 & 2027
  • ISRAEL
    • TABLE 97: Israel Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Israel Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 99: Israel 15-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2020 & 2027
  • SAUDI ARABIA
    • TABLE 100: Saudi Arabia Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 101: Saudi Arabia Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 102: Saudi Arabia 15-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2020 & 2027
  • UNITED ARAB EMIRATES
    • TABLE 103: UAE Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 104: UAE Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 105: UAE 15-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2020 & 2027
  • REST OF MIDDLE EAST
    • TABLE 106: Rest of Middle East Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 107: Rest of Middle East Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 108: Rest of Middle East 15-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2020 & 2027
  • AFRICA
    • TABLE 109: Africa Current & Future Analysis for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 110: Africa Historic Review for Fibromyalgia Therapeutics by Drug Class - Antiepileptics, Antidepressants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 111: Africa 15-Year Perspective for Fibromyalgia Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Antiepileptics, Antidepressants and Other Drug Classes for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 22